Precision BioSciences (NASDAQ:DTIL) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Precision BioSciences (NASDAQ:DTIL) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other analysts have also recently commented on DTIL. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Oppenheimer initiated coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday, August 5th. Finally, JonesTrading reissued a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research report on Friday, April 17th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Precision BioSciences presently has an average rating of “Moderate Buy” and an average price target of $32.25.

Precision BioSciences Trading Down 0.4%

DTIL opened at $7.46 on Friday. The stock has a market cap of $205.90 million, a PE ratio of -2.66 and a beta of 1.27. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $7.37 and a 200-day moving average of $6.37. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. Equities research analysts predict that Precision BioSciences will post -2.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Precision BioSciences during the second quarter valued at approximately $467,000. Bank of America Corp DE lifted its position in Precision BioSciences by 167.6% in the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after acquiring an additional 17,172 shares in the last quarter. Quantinno Capital Management LP bought a new position in Precision BioSciences in the 1st quarter valued at approximately $104,000. Octagon Capital Advisors LP boosted its stake in Precision BioSciences by 16.6% during the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after purchasing an additional 318,737 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Precision BioSciences during the 1st quarter valued at $3,289,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.